Existing patents deter the marketing of more affordable generic drugs that could be used off-label for abortions.
Recent abortion pill litigation underscores the significance of calls to make birth control pills available over the counter.
Scholars examine regulatory solutions for improving behavioral health care.
Scholars identify avenues to curb regulatory barriers to substitution therapy.
Scholar argues that loopholes in U.S. food regulation put consumers at risk.
Scholar calls for FDA to remove stringent restrictions on medication abortion.
Anti-abortion advocates take aim at FDA approval and regulation of the abortion drug mifepristone, threatening access nationwide.
Scholar argues that Congress and FDA should treat risky clinical artificial intelligence tools as medical devices.
FDA’s approach to evidence-based decision-making may not be addressed to the right people.
Experts contend that FDA clinical trials fail to ensure adequate consideration of women’s health needs.
Exploring FDA’s toolkit for encouraging study sponsors to meet diversity goals.
Scholars explore regulatory reforms to expand noncitizens’ access to health care.